CAR T as Frontline Therapy for DLBC Lymphoma: Alex Herrera, MD


The hematologist/oncologist from City of Hope discussed the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Alex Herrera, MD, hematologist/oncologist, and assistant professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, about the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma (DLBCL).

Standard salvage chemotherapy or autologous stem cell transplant are often used to treat patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, but several ongoing trials are examining whether autologous CD19-directed CAR T cells can be utilized earlier than these standards of care.

Herrera discussed ongoing trials such as the phase 3 ZUMA-7 trial (NCT03391466) examining axicabtagene ciloleucel (axi-cel; Yescarta) vs standard of care as second-line therapy in patients with relapsed/refractory DLBCL. He discussed how CAR T-cell therapy may become the standard second-line treatment for this patient population if these trials show positive results.

Additionally, the phase 2 ZUMA-12 trial (NCT03761056), which is evaluating CAR T cells in patients receiving frontline therapy who have a positron emission tomography scan that is positive after 2 cycles of systemic chemotherapy, has shown promising results, Herrera adds. CAR T-cell therapy will continue to be evaluated in high-risk groups of patients who are progressing, or who show signs of early progression with their frontline therapy, Herrera concludes.

Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
© 2024 MJH Life Sciences

All rights reserved.